-
Olapali's new indications are planned to be included in the priority review for the treatment of prostate cancer
Time of Update: 2021-01-31
On January 21, CDE's official website showed that AstraZeneca's application for the listing of new indications for the Olapali tablet was to be included in the priority review, a single drug used to treat adult patients with BRCA1/2 mutations (embryo and/or somatic cell line) who developed disease progression after previous new hormone therapy.
-
Professor Meng Zhiqiang | IMbrave150's OS results are "another success" and "T-A" opens a new chapter in HCC treatment
Time of Update: 2021-01-30
China is a "big country of liver cancer", China's annual liver cancer cases and deaths accounted for more than half of the world. the emergence of immuno combination therapy, for liver cancer immunot
-
Platinum-sensitive relapsed ovarian cancer: Capra-Dorobi-Beval bead monoantin may be the new standard treatment
Time of Update: 2021-01-30
A randomized, open-label Phase III.phase III clinical trial reported by Pfisterer at the Gynaecological Oncology Center in Kiel, Germany, showed that carptonin-polyglycol liposome polyflexostar-beva bead monoantigen is a new standard treatment option for platinum-type relapsed ovarian cancer.
-
Nat Med: Comparison of Durvalumab in metastasis breast cancer with the efficacy of maintaining chemotherapy
Time of Update: 2021-01-30
the study presented the results of a Phase II randomized trial, SAFIR02-BREAST IMMUNO, and biomarker analysis, which compared the effects of anti-PD-L1 antibodies (durvalumab, deveryu monoantigen) with maintenance chemotherapy in patients with Her2-negative mBC.
-
Relapsed or late-stage mismatch repair defects of endometrial cancer: clinical activity and safety of Dostarlimab
Time of Update: 2021-01-30
as of the data, a total of 104 patients with endometrial cancer (with a medium age of 64.0 years, ranging from 38 to 80 years of age) were treated with Dostarlimab.
-
ESGO || Clinical advice for patients with endometrial cancer to retain reproductive function
Time of Update: 2021-01-30
Before performing conservative treatment on EC patients, the attending physician should consider two questions: first, evaluating the clinical pathological and biological behavior of the tumor, such as histological credit type, gradation, degree of muscle immersion, pulse immersion, and second, determining the best drug, dosage, treatment time, and follow-up plan.
-
Yew alcohol peritherapy: a new option for the treatment of relapsed interstitium tumors
Time of Update: 2021-01-30
The purpose of this study was to determine the efficacy of weekly beechol joint or non-combined beva bead anti-treatment of relapsed melanosophon tumors, and to assess whether adding beech bead monoantigen to weekly yew alcohol increased the rate of progression without progression for 6 months.
-
Silly can't tell || ORR, DCR, PFS, OS, what are the objective indicators for evaluating tumor outcomes?
Time of Update: 2021-01-30
Objective mitigation rate is a direct measure of drug anti-tumor activity and can be evaluated in one-arm trials (but it is worth noting that single-arm trials do not adequately reflect time-event endpoints, such as PFS and OS, so randomized controlled studies are required when using time-event endpoint indicators).
-
Cervical cancer || Disease-free survival of minimally invasive root-and-glycation hysterectomy
Time of Update: 2021-01-30
A multi-agency retrospective series of studies reported by uppal at the University of Michigan in the United States showed that patients who received minimally invasive root-and-glycation hysterectomy,including a final pathologically determined tumor of ≤ 2 cm, had poor disease-free survival (DFS), but had better overall survival rates across the queue.
-
Br J Cancer:CirCe01 randomized trial analyzes the clinical usefulness of chemotherapy surveillance strategies based on circulating tumor cells in patients with metastasis breast cancer
Time of Update: 2021-01-30
The CirCe01 trial was designed in this study, the researchers reported the results of the CirCe01 trial, a forward-looking CTC-based trial designed to assess the clinical usefulness of CTC-based monitoring for MPC patients after third-line chemotherapy (LC).
-
Cervical adenocarcinoma: Pattern classification
Time of Update: 2021-01-30
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
-
Cochrane Answer: Can hormone replacement supplements be used in endometrial cancer patients after comprehensive treatment?
Time of Update: 2021-01-30
includes randomized controlled trials (RCTs) in all languages, which provide the effectiveness of symptom relief and the safety of using HRT to treat women with endometrial cancer, which is considered to do not increase the risk of recurrence of endometrial cancer compared to women who do not use HRT.
-
The French National Gynaecological and Obstetrics and Gynaecology Hospital (CNGOF) Guidelines for Ovarian Junction Oncology (2020, upper) || Epidemiology, Biopathology, Imaging and Biomarkers
Time of Update: 2021-01-30
Abstract: The incidence of junction ovarian tumors (BOTs) increases with age, the middle age of onset is 46 years old, from 15-19 years old, 55-59 years of age peak, the annual incidence rate is about
-
Another "unlimited cancer" anti-cancer drug has been approved clinically in China
Time of Update: 2021-01-30
August 2019, Entrectinib was approved by the FDA to treat adult and child solid tumor patients with NTRK gene fusion without other effective treatments, as well as patients with ROS1-positive non-small cell lung cancer (NSCLC).
-
Endometrial cancer: predictive lymph node metastasis model
Time of Update: 2021-01-30
A study by Berg and others at the University of Berg in Norway demonstrated that data-driven predictive models that add protein markers to clinical information about endometrial cancer (EEC) have significant potential for improving diagnosis in patients with preoperative lymph node metastasis (LNM).
-
JCO || Relapse or persistent ovarian cancer: The remission rate of Navuliyu monoantigen is high
Time of Update: 2021-01-30
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
-
Low-grade slurry ovarian cancer: Binimetinib efficacy needs to be further verified
Time of Update: 2021-01-30
A randomized study (MILO/ENGOT-ov11) reported by Monk and others at the University of Arizona School of Medicine showed that although the MEK inhibitor Binimetinib in the low-grade slurry ovarian cancer (LGSOC) study showed anti-tumor activity in the end-of-efficacy assessment, kraS mutations predicted reactions to Binimetinib.
-
WCLC2020 attacks on the precision treatment of lung cancer, to see what the breakthrough of the popular targets
Time of Update: 2021-01-30
currently, Keystone Pharmaceuticals has submitted a listing application to the National Drug Administration (NMPA) for platini's treatment of RET fusion-positive NSCLC patients with platinum-containing chemotherapy, which was accepted and included in the priority review on September 7, 2020.
-
Effect of uterine approidation on tumor prognosis in endometrial cancer patients: a retrospective study from 15 gynaecological oncology centers in Spain
Time of Update: 2021-01-30
the patients in this study underwent laparoscopic surgery, and the use of uterine uterine devices was associated with adverse prognostic outcomes of tumors in patients with endometrial cancer (FIGOI-II) that was confined to the uterus.
-
Eur Radiol: What exactly is liver cell liver cancer without fast-forwarding and fast-out?
Time of Update: 2021-01-30
The qualitative diagnosis of hepatocellular liver cancer (HCC) does not require biopsy to a great extent, and the qualitative diagnosis can be achieved by relying solely on imaging characteristics. a
